Official Records on Prescription Medicines
The Agency for Medicinal Products and Medical Devices of Bosnia and Herzegovina issues annual reports on utilization of pharmaceuticals nationwide. These annual reports are commercially available since 2009 (12) . This source contains data on medicines prescription, dispensing, and sales provided directly by the pharmaceutical multinationals and domestic manufacturers. Wholesalers are required to provide data on the number of packages of drugs that are imported and wholesale price. This price usually consists of manufacturer's price plus customs, incremental costs, and the wholesale markup. Domestic producers were required to provide data on the number of packages of drugs that are produced and released into the market with wholesale price (manufacturer's price plus the wholesale markup). Costs are expressed in Bosnia and Herzegovina's local currencyconvertible mark (BAM). Data are ordered in ATC (Anatomical-Therapeutical-Chemical) codes on first, second, third, fourth, and fifth level of classification (13). Latest report has been made in 2014 for the year 2013. Total of 39 wholesalers provided data. The ratio of domestic and foreign manufacturers of medicines in the total turnover of pharmaceuticals in 2013 was 17 vs. 83% (14) . Population health official estimate is being issued annually by the Public Health Institute of the Republic of Srpska (15). It provides us with exact data with regard to health facilities, staffing, and the structure of spending (public and private expenditure). Third source of data supporting these claims was the Agency for Statistics' publications on gross domestic product and National Health Accounts Statistics for the period from 2009 to 2013 (16).
Ongoing Pharmaceutical Market Transformation 2009-2013
Observing 5-year time horizon (2009-2013), we see that moderate growth of pharmaceutical market took place. Some ATC code groups recorded far more substantial market changes than others. Thus, systemic hormonal preparations, excluding sex hormones, and insulin value-based turnover increased for 92%, and antiparasitic products, insecticides, and repellents spending decreased for 63%. Changes were also significant in the indication field of blood and blood-forming organs reporting 36% growth, as well as antineoplastic and immunomodulating agents, sensory organs, respiratory system, and alimentary tract and metabolism drugs which increased their sales volume around 30% each. Top 10 ATC second-level code groups in 2009 and 2013 have been renin-angiotensin system agents, antibacterials for systemic use, antineoplastic agents, psycholeptics, drugs used in diabetes, drugs for acid-related disorders, analgesics, calcium channel blockers, anti-inflammatory and antirheumatic products, beta blocking agent, and antithrombotic agents. Consumption of preparations for wounds and ulcers treatment has increased three times. Nasal preparations, digestives, including enzymes, pituitary and hypothalamic hormones, and prescribing antigout preparations have also increased twofold ( Table 1) .
Differences in certain ATC drug group consumption are reflecting the changes that have been happening in the national health system. Prices have been reduced, especially for generic drugs where patent protection has expired. A lot of effort has been invested in the implementation of good clinical practice guidelines. That is the reason for reducing antibiotics consumption outsourcing from decreased frequency of nosocomial infections and overprescribing by general practice physicians. Development of novel targeted antineoplastic medicines, primarily the biologicals, as well as increased incidence of malignant diseases influenced constant growth of utilization. The level of obesity is increasing and so is antidiabetics consumption as well as pharmaceuticals indicated in cardiovascular and associated diseases. 
Forecasts of Future Changes
Although there are some promising developments, local pharmaceutical market structure and dynamics is still far from the one responsive to population needs. In the country still recovering from unstable political situation over the last few decades, a lot of progress has been made. The Health Insurance Fund is consistently negotiating with pharmaceutical companies imposing price caps and generic substitution wherever possible. Thus, Fund created more room for innovative therapies reimbursement. That is why authorities are considering marketing approvals of novel drugs indicated in hepatitis, diabetes, targeted antineoplastic agents (17), as well as immunotherapy, which we expect to be available to the patients over the next 5-10 years. Western Balkan countries share post-socialist legacy of former Yugoslavia in health care management and financing patterns (18) . Quite similar but faster development in a large-scale population could be observed in neighboring Serbia (19) . This country suffered as well from seriously constrained resource allocation for medicines during global economic recession (20) . Signs of early recovery are now clearly present particularly in the oncology indication field (21) . Accessibility and affordability of innovative therapies gradually became reality for even the poorest citizens (22) .
The Republic of Srpska due to its smaller population size might have more convenient opportunity for sustainable health policy solutions learning from painful lessons of other South-East European transitional health reforms (23) . Current developments nationwide present a promise of more responsive pharmaceutical market. The country is likely to be capable of providing more affordable, mostly generic medicines in the upcoming years.
